hTIGIT

Nomenclature

C57BL/6Smoc-Tigitem1(hTIGIT)Smoc

Cat. NO.

NM-HU-00053

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
TIGIT

Model Description

The endogenous mouse Tigit gene was replaced by human TIGIT gene. While hTIGIT(3)(Stock No.NM-HU-200244) mice function similarly to hTIGIT mice,for more detailed information please contact our technical advisor.
Research Application:Immunotherapy,cancer research,drug screening

Validation Data

image.png

Figure 1. Expression of human TIGIT in the polarized CD4+ T cells of humanized TIGIT mice is detected by FACS. Spleen Naive CD4+ T cells were isolated from heterozygous humanized TIGIT mice. After in vitro stimulation, activation and expansion by cytokines and antibodies, the CD4+ T cells were re-stimulated with PMA/ionomycin before the expression of human TIGIT in polarized CD4+ T cells was detected by FACS. The results showed that the active expression of human TIGIT could be detected in polarized CD4+ T cells collected from humanized TIGIT mice, and the expression trend of human TIGIT was similar to that of murine TIGIT.

tigit-tumor volume.png


tigit-body weight.png

Fig 2. In vivo validation of anti-tumor efficacy in a Hepa1-6 tumor-bearing model of humanized TIGIT mice. Homozygous humanized TIGIT mice were inoculated with Hepa1-6 cells. After the tumors grew to 110 mm3, the animals were randomly assigned into a control group and a treatment group. The results showed a significant anti-tumor effect was observed when the antibody targeting human TIGIT. (Completed in collaboration with CrownBio).

tigit 药效.png

tigit 药效-1.png

Fig 3. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized TIGIT mice. Homozygous humanized TIGIT mice were inoculated with MC38 colon cancer cells. After the tumors grew to 130 mm3, the animals were randomly assigned into a control group and a treatment group (n=7). The results showed a significant anti-tumor effect was observed when the antibody targeting human TIGIT was administered together with Anti-PD-L1 analogue. (Completed in collaboration with Harbour BioMed).


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more